Lysostaphin in treatment of neonatal Staphylococcus aureus infection

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 6, 2007, Pages 2198-2200

  Oluola, Okunola ^a,b   Kong, Lingkun ^a   Fein, Mindy ^a   Weisman, Leonard E ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOSTAPHIN; NAFCILLIN; OXACILLIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; ENDOCARDITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEWBORN INFECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANIMALS, SUCKLING; ANTI-INFECTIVE AGENTS, LOCAL; DISEASE MODELS, ANIMAL; HUMANS; INFANT, NEWBORN; LYSOSTAPHIN; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; RATS; RATS, WISTAR; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 34250195356     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00506-06     Document Type: Article

References (28)

1. Agapitova, I. V., V. I. Bobrov, V. I. Trubnikov, and V. P. Iakovlev. 1984. Penetration of ampicillin and oxacillin into the tissues of rats with aseptic inflammation. Antibiotiki 29:370-373. (In Russian.)
2. Cantoni, L., A. Wenger, M. P. Glauser, and J. Bille. 1989. Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats. J. Infect. Dis. 159:989-993.
3. Chambers, H. F. 1997. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev. 10:781-791.
4. Chapman, R. L., and R. G. Faix. 2003. Persistent bacteremia and outcome in late onset infection among infants in a neonatal intensive care unit. Pediatr. Infect. Dis. J. 22:17-21.
5. Climo, M. W., K. Ehlert, and G. L. Archer. 2001. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:1431-1437.
6. Climo, M. W., R. L. Patron, B. P. Goldstein, and G. L. Archer. 1998. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob. Agents Chemother. 42:1355-1360.
7. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Dajcs, J. J., B. A. Thibodeaux, E. B. Hume, X. Zheng, G. D. Sloop, and R. J. O'Callaghan. 2001. Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit. Curr. Eye Res. 22:451-457.
9. Karchmer, T. B., L. J. Durbin, B. M. Simonton, and B. M. Farr. 2002. Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. 51:126-132.
10. Kaufman, D., and K. D. Fairchild. 2004. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin. Microbiol. Rev. 17:638-680.
11. Kokai-Kun, J. F., S. M. Walsh, T. Chanturiya, and J. J. Mond. 2003. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob. Agents Chemother. 47:1589-1597.
12. Kopp, B. J., D. E. Nix, and E. P. Armstrong. 2004. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann. Pharmacother. 38:1377-1382.
13. Lodise, T. P., and P. S. McKinnon. 2005. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn. Microbiol. Infect. Dis. 52:113-122.
14. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
15. Martin, R. R., and A. White. 1967. The selective activity of lysostaphin in vivo. J. Lab. Clin. Med. 70:1-8.
16. Mori, H., T. Nakajima, A. Nakayama, M. Yamori, F. Izushi, and Y. Gomita. 1998. Interaction between levofloxacin and vancomycin in rats - study of serum and organ levels. Chemotherapy 44:181-189.
17. Navarre, W. W., and O. Schneewind. 1999. Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol. Mol. Biol. Rev. 63:174-229.
18. NCCLS/CLSI. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 6th ed. M7-A6. NCCLS, Wayne, PA.
19. Oldham, E. R., and M. J. Daley. 1991. Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic. J. Dairy Sci. 74:4175-4182.
20. Schindler, C. A., and V. T. Schuhardt. 1964. Lysostaphin: a new bacteriolytic agent for the staphylococcus. Proc. Natl. Acad. Sci. USA 51:414-421.
21. Schito, G. C. 2006. The importance of the development of antibiotic resistance in Staphylococcus aureus. Clin. Microbiol. Infect. 12(Suppl. 1):3-8.
22. Stark, F. R., C. Thornsvard, E. P. Flannery, and M. S. Artenstein. 1974. Systemic lysostaphin in man-apparent antimicrobial activity in a neutropenic patient. N. Engl. J. Med. 291:239-240.
23. Stoll, B. J., N. Hansen, A. A. Fanaroff, L. L. Wright, W. A. Carlo, R. A. Ehrenkranz, et al. 2002. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 110: 285-291.
24. Stranden, A. M., K. Ehlert, H. Labischinski, and B. Berger-Bachi. 1997. Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J. Bacteriol. 179:9-16.
25. Trayer, H. R., and C. E. Buckley III. 1970. Molecular properties of lysostaphin, a bacteriolytic agent specific for Staphylococcus aureus. J. Biol. Chem. 245:4842-4846.
26. Walsh, S., A. Shah, and J. Mond. 2003. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob. Agents Chemother. 47:554-558.
27. Weisman, L. E. 2004. Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient. Curr. Opin. Infect. Dis. 17:237-241.
28. Wu, J. A., C. Kusuma, J. J. Mond, and J. F. Kokai-Kun. 2003. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob. Agents Chemother. 47:3407-3414.